TNFRSF8 and plasma cell myeloma: The targeting of CD30 has an important and emerging role in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30-positive malignancies.29 CD30 has restricted expression in normal tissues, but is widely expressed in Hodgkin’s disease, anaplastic large cell lymphoma, non-Hodgkin’s lymphoma, multiple myeloma and cutaneous T-cell lymphoma.21,30 We showed that CD30-positive cell lines were sensitive to anti-CD30-MCC-DM1 cytotoxicity in vitro.